You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Alembic Pharma gains after Q4 PAT rises 12% to Rs 251 cr

Capital Market 

Alembic Pharmaceuticals rose 1.67% to Rs 999.40 after the company's consolidated net profit jumped 12% to Rs 251 crore on 6% increase in net sales to Rs 1,280 crore in Q4 FY21 over Q4 FY20.

On a consolidated basis, the company's net profit jumped 42% to Rs 1178 crore on 17% increase in net sales to Rs 5393 crore in the year ended March 2021 over the year ended March 2020.

International formulations jumped 19% Y-o-Y (year-on-year) to Rs 2,942 crore in FY21 over FY20. US Generics spurted 9% Y-o-Y to Rs 2,163 crore in FY21 over FY20. Ex-US International Formulations soared 57% Y-o-Y to Rs 779 crore in FY21.

13 ANDA's were filed in the quarter and 29 ANDA filings for the year. Research & Department (R&D) spend was reported at 12% of revenue or Rs 670 crore for the year.

India branded formulations business grew 5% to Rs 1,497 crore in FY21 from FY20. API business grew 38% Y-o-Y to Rs 214 crore in the quarter and 35% Y-o-Y to Rs 955 crore in FY21 over FY20. Two Drug Master File (DMF) were filed in the quarter while the cumulative DMF fillings stood at 117.

Pranav Amin, the managing director of Alembic Pharmaceuticals, said: "It was an outstanding year with the company recording its highest sales and profit ever. This was led by strong growth in the API and International Business. The operating teams worked tirelessly through the pandemic to ensure critical supplies were uninterrupted."

The board has recommended a dividend of Rs 14 per share.

Meanwhile, Alembic Pharmaceuticals announced that its joint venture Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Metronidazole Gel USP, 1%.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Metrogel Gel, 1 %, of Galderma Laboratories LP (Galderma). The product is indicated for Indicated for the topical treatment of inflammatory lesions of rosacea.

Metronidazole Gel USP, 1% has an estimated market size of $32 million for twelve months ending December 2020 according to IQVIA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, May 04 2021. 15:48 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU